Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.50 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | USP7 | Q93009 | 1/20 | 0.38 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.36 |
| ▸ | PLG | P00747 | 2/20 | 0.36 |
| ▸ | QDPR | P09417 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28049564 | 0.88 | HRH4 (0.45) | HRH4HTR2C | |
| SCHEMBL14240499 | 0.87 | HRH4 (0.44) | HRH4TLR9TLR8TLR7HTR2C | |
| SCHEMBL16789827 | 0.84 | PDE10A (0.42) | HRH4MAPTTDP1 | |
| SCHEMBL24067526 | 0.79 | SLC18A3 (0.42) | HRH4USP7SLC18A3SIGMAR1HRH3 | |
| SCHEMBL2176046 | 0.78 | BACE1 (0.44) | HRH4MAPTALDH1A1 | |
| SCHEMBL1914881 | 0.78 | HRH4 (0.53) | HRH4USP7SLC18A3SIGMAR1HRH3 | |
| SCHEMBL2034798 | 0.77 | CHEK1 (0.47) | HRH4 | |
| SCHEMBL3567520 | 0.77 | MKNK1 (0.44) | HRH4MKNK1MKNK2USP7SLC18A3 | |
| Hydrochloric Acid SCHEMBL20292168 | 0.76 | MKNK1 (0.43) | HRH4MKNK1MKNK2USP7SLC18A3 | |
| Hydrochloric Acid SCHEMBL30616831 | 0.76 | MKNK1 (0.43) | HRH4MKNK1MKNK2USP7SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4777244-B2 | — | — | 2011-09-21 | — | — | JP | claimed |
| US-8198232-B2 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100298333-A1 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100291589-A1 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100286153-A1 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100286111-A1 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100285494-A1 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100286168-A1 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100286172-A1 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100285495-A1 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| US-7803753-B2 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803754-B2 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-20100137293-A1 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20070072804-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070072803-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS (US) | 2007-03-29 | — | — | US | disclosed |
| US-20060154866-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072803-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | GLP1R, GPR119, GIPR | HRH4 439/4885MKNK1 3767/4885MKNK2 3674/4885 |
| US-20100286168-A1 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | GLP1R, GPR119, GIPR | HRH4 439/4885MKNK1 3767/4885MKNK2 3674/4885 |
| US-20070072804-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | GLP1R, GPR119, GIPR | HRH4 439/4885MKNK1 3767/4885MKNK2 3674/4885 |
| US-20100137293-A1 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | GLP1R, GPR119, GIPR | HRH4 439/4885MKNK1 3767/4885MKNK2 3674/4885 |
| US-20100286172-A1 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | GLP1R, GPR119, GIPR | HRH4 439/4885MKNK1 3767/4885MKNK2 3674/4885 |
| US-20060154866-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | GLP1R, GPR119, GIPR | HRH4 439/4885MKNK1 3767/4885MKNK2 3674/4885 |
| US-20100286111-A1 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | GLP1R, GPR119, GIPR | HRH4 439/4885MKNK1 3767/4885MKNK2 3674/4885 |
| US-20100298333-A1 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | GLP1R, GPR119, GIPR | HRH4 439/4885MKNK1 3767/4885MKNK2 3674/4885 |
| US-20100286153-A1 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | GLP1R, GPR119, GIPR | HRH4 439/4885MKNK1 3767/4885MKNK2 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.